Autoimmune Myositis
Nov 10, 2026
argenx’s ALKIVIA Phase 3 Study Demonstrates Rapid and Durable Clinical Improvement with Efgartigimod in Autoimmune Myositis; Johnson & Johnson Reports Phase 2 Nipocalimab Data in Sjögren’s Disease Highlighting Patient-Prioritized Symptom Improvements; Immunocore Unveils Promising Brenetafusp–KIMMTRAK Data in Metastatic Uveal Melanoma; Real-World Study Shows REPATHA Cuts Heart Attack Risk by 20% Compared with Ezetimibe; Health Canada Approves Moderna’s mRNA Flu Vaccine and Combined Influenza-COVID-19 Vaccine
argenx Shares Phase 3 ALKIVIA Evidence of Rapid and Sustained Efgartigimod Response in Autoimmune Myositis argenx SE announced that findings from the Phase 3 ALKIVIA study, highlighting the rapid and sustained clinical improvement achieved with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patie...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
